Integrated Approaches to Testing and Assessment (IATA) ex. Skin Sensitisation

Size: px
Start display at page:

Download "Integrated Approaches to Testing and Assessment (IATA) ex. Skin Sensitisation"

Transcription

1 Integrated Approaches to Testing and Assessment (IATA) ex. Skin Sensitisation João Barroso 10 th EPAA Annual Conference Brussels, 2014

2 Conventional Toxicology Chemical Animal model Pancreatic tumor Observe adverse effects Animal-intensive Questionable human relevance Expensive Very time-consuming 2

3 Vision: Next Generation Safety Assessment Biological Profiling Cell cultures 3D tissues Genomics Cheminformatics Exposure modeling DATA INTEGRATION PREDICT SAFETY 3

4 Integrated Approaches to Testing and Assessment (IATA): Proposed Working Definition A structured approach used for hazard identification (potential), hazard characterisation (potency) and/or safety assessment (potential/potency and exposure) of a chemical or group of chemicals, which strategically integrates and weights all relevant data to inform regulatory decision regarding potential hazard and/or risk and/or the need for further targeted and therefore minimal testing. 4

5 Integrated Approaches to Testing and Assessment (IATA): Proposed Working Definition Where sufficient understanding of Adverse Outcome Pathways (AOPs) exists, such framework would provide a solid scientific basis for development of IATA. Within such an AOP-driven IATA, the different information used to inform a regulatory decision would target key events along the defined toxicity pathway. 5

6 Skin Sensitisation: First Case of AOP-driven IATA Development Chemical Structure & Properties Molecular Initiating Event Cellular Response Organ Response Organism Response Metabolism Penetration Electrophilic substance Key Event 1 Covalent interaction with skin proteins Key Event 3 Dendritic Cells (DCs) Induction of inflammatory cytokines and surface molecules Mobilisation of DCs Key Event 2 Keratinocyte responses Activation of inflammatory cytokines Induction of cytoprotective genes Key Event 4 T-cell proliferation Histocompatibility complex presentation by DCs Activation of T cells Proliferation of activated T-cells Adverse Outcome Inflammation upon challenge with allergen The Adverse Outcome Pathway for Skin Sensitisation Initiated by Covalent Binding to Proteins; Part 1: Scientific Evidence Series on Testing and Assessment No.168 ENV/JM/MONO(2012)10/PART1 6

7 From Adverse Outcome Pathways to Practical Applications priority setting hazard identification Integrated Approaches to Testing and Assessment (IATA) classification & labelling risk assessment Mechanistic information toxicokinetics Adverse Outcome Pathways Alternative Methods Toolbox in chemico assays in vitro assays in silico models chemical categories 7

8 Information Sources within IATA Physico-chemical data In silico data In chemico data In vitro data In vivo data Exposure considerations Assessment using WoE or predefined approaches or combination of both 8

9 Examples of Published Data Integration Strategies for Skin Sensitisation Nukada et al. (2013) Toxicology in Vitro 27, Jaworska et al. (2013) Journal of Applied Toxicology Bauch et al. (2012) Regulatory Toxicology and Pharmacology 63,

10 Development of IATA for skin sensitisation Several possibilities of combining information (contextspecific and substance-tailored). Some information will be covered by Mutual Acceptance of Data (MAD), but final decision will not. There is therefore a risk of disharmonisation in the application and interpretation of IATA. Proper guidance is crucial! 10

11 OECD Project: Development of a Guidance Document on the Evaluation and Application of IATA for Skin Sensitisation Led by the European Commission Project run under TF-HA (endorsed in June 2013) Currently under development 11

12 Aims of the EC Led OECD Project Develop an AOP-driven IATA framework covering different regulatory needs across multiple industry sectors. Provide guidance on the development, evaluation and application of IATA. Provide a consistent description of individual information sources to allow for easy comparison between methodologies. To develop a harmonised template for describing IATA solutions. To include examples of compiled case studies. 12

13 Six Principles: Essential Information for Regulatory Application of an IATA 1. A defined endpoint 2. A defined purpose 3. A description of the rationale underlying the construction of the IATA 4. A description of the individual information sources constituting the IATA 5. A description of how the individual information sources are integrated to derive the final prediction/assessment 6. A description of the known uncertainties associated with the IATA application 13

14 Food for Thought Lots of mechanistic knowledge exists but not being sufficiently explored to support the use of alternatives for safety assessment decisions (via IATA) This knowledge should be collected, evaluated and used to generate further AOP knowledge and guide method development and application in safety assessment But, in the short term, it should be better used to facilitate the regulatory acceptance of mechanistically based methods and support the development of mechanistically informed IATA 14

15 Thank you for your attention! Joint Research Centre (JRC) The European Commission s in-house science service Serving society - Stimulating innovation - Supporting legislation 15

Cosmetics Europe LRSS Programme

Cosmetics Europe LRSS Programme Cosmetics Europe LRSS Programme 2016-20 Rob Taalman Objectives of CE Research To deliver tools & strategies for animal-free safety assessment Accurate Robust Efficient ultimately accepted by regulators

More information

NON-ANIMAL APPROACHES TO SAFETY ASSESSMENT OF COSMETIC PRODUCTS. Cutting-Edge Science and Constant Innovation: The Keys to Success

NON-ANIMAL APPROACHES TO SAFETY ASSESSMENT OF COSMETIC PRODUCTS. Cutting-Edge Science and Constant Innovation: The Keys to Success NON-ANIMAL APPROACHES TO SAFETY ASSESSMENT OF COSMETIC PRODUCTS Cutting-Edge Science and Constant Innovation: The Keys to Success 2 NON-ANIMAL APPROACHES TO SAFETY ASSESSMENT OF COSMETIC PRODUCTS Cutting-Edge

More information

OVERVIEW OF THE OECD PROJECT ON ASSESSMENT OF COMBINED EXPOSURES TO MULTIPLE CHEMICALS

OVERVIEW OF THE OECD PROJECT ON ASSESSMENT OF COMBINED EXPOSURES TO MULTIPLE CHEMICALS OVERVIEW OF THE OECD PROJECT ON ASSESSMENT OF COMBINED EXPOSURES TO MULTIPLE CHEMICALS EuroMix Stakeholder Workshop - Brussels 18 May, 2017 Eeva Leinala Principal Administrator Hazard Assessment Programme

More information

Tox21: Opportunities& Challenges. Richard A. Becker Ph.D., DABT American Chemistry Council

Tox21: Opportunities& Challenges. Richard A. Becker Ph.D., DABT American Chemistry Council Tox21: Opportunities& Challenges Richard A. Becker Ph.D., DABT American Chemistry Council October 21, 2010 Opportunities and Challenges The manifest challenge is to develop in vitro and in silico approaches

More information

DISCOVER OUR SEGMENT REGULATORY SCIENCE

DISCOVER OUR SEGMENT REGULATORY SCIENCE DISCOVER OUR SEGMENT REGULATORY SCIENCE Our focus In the demanding regulatory environment of the EU, expert knowledge is essential to gaining approval for substances and products. That is why the scientific

More information

Integrated Testing Strategies for REACH. Perspective from the European Chemicals Agency

Integrated Testing Strategies for REACH. Perspective from the European Chemicals Agency Integrated Testing Strategies for REACH Perspective from the European Chemicals Agency Jack de Bruijn Directorate for Assessment European Chemicals Agency SETAC EUROPE Special Science Symposium, 23-24

More information

The Long Range Science Strategy (LRSS) of Cosmetics Europe

The Long Range Science Strategy (LRSS) of Cosmetics Europe The Long Range Science Strategy (LRSS) of Cosmetics Europe Repeated dose systemic toxicity 2016 Bas Blaauboer Aim of LRSS: Development of a strategy to determine safety of cosmetic ingredients and products

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS European Medicines Agency London, 24 January 2008 Doc. Ref. EMEA/CHMP/SWP/258498/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS

More information

Alternative Testverfahren und intelligente Teststrategien Position der EU-Kommission. Thomas Hartung & ECVAM Team.

Alternative Testverfahren und intelligente Teststrategien Position der EU-Kommission. Thomas Hartung & ECVAM Team. Alternative Testverfahren und intelligente Teststrategien Position der EU-Kommission Thomas Hartung & ECVAM Team Institute for Health and Consumer Protection (IHCP) Ispra (Va), Italy http://ecvam.jrc.it

More information

HARMONISING ENVIRONMENTAL RISK ASSESSMENTS OF PESTICIDES

HARMONISING ENVIRONMENTAL RISK ASSESSMENTS OF PESTICIDES HARMONISING ENVIRONMENTAL RISK ASSESSMENTS OF PESTICIDES OECD DEVELOPMENT OF TEST GUIDELINES AND METHODOLOGIES EFSA Scientific Conference on ERA of pesticides Parma, 15-16 November 2016 OECD Secretariat

More information

Category approaches, Read-across, (Q)SAR

Category approaches, Read-across, (Q)SAR Category approaches, Read-across, (Q)SAR Technical Report No. 116 EUROPEAN CENTRE FOR ECOTOXICOLOGY AND TOXICOLOGY OF CHEMICALS Category approaches, Read-across, (Q)SAR Technical Report No. 116 Brussels,

More information

Justification Document for the Selection of a CoRAP Substance

Justification Document for the Selection of a CoRAP Substance Justification Document for the Selection of a CoRAP Substance Substance Name (public name): 1,1'-(isopropylidene)bis[3,5-dibromo- 4-(2,3-dibromopropoxy)benzene] EC Number: 244-617-5 CAS Number: 21850-44-2

More information

Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development

Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development Unclassified ENV/JM/MONO(2016)48 ENV/JM/MONO(2016)48 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 12-Sep-2016 English

More information

Addressing Complex Challenges Posed by Hazardous Substances

Addressing Complex Challenges Posed by Hazardous Substances Addressing Complex Challenges Posed by Hazardous Substances William A. Suk, Ph.D., M.P.H. Director, Superfund Research Program Chief, Hazardous Substances Research Branch Division of Extramural Research

More information

FDA Perspective on the Preclinical Development of Cancer Vaccines

FDA Perspective on the Preclinical Development of Cancer Vaccines FDA Perspective on the Preclinical Development of Cancer Vaccines Richard D. McFarland Ph.D., M.D. Medical Officer CBER/OCTGT/DCEPT mcfarlandr@cber.fda.gov Cancer Vaccine Clinical Trials Workshop Alexandria,

More information

Structure and content of an IMPD. What is required for first into man trial?

Structure and content of an IMPD. What is required for first into man trial? What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation

More information

Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development

Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development Unclassified ENV/JM/MONO(2016)67 ENV/JM/MONO(2016)67 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 19-Dec-2016 English

More information

Guidance for the identification of endocrine disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 1107/2009

Guidance for the identification of endocrine disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 1107/2009 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Guidance for the identification of endocrine disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 1107/2009 Draft

More information

CEFIC LRI Project EEM9.3

CEFIC LRI Project EEM9.3 REACH INFORMATION & EXPERIENCE EXCHANGE FORUM IV 19 JUNE 2015 CEFIC LRI Project EEM9.3 Linking LRI AMBIT Chemoinformatic System with the IUCLID Substance Database to Support Read across of Substance Endpoint

More information

Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development

Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development Unclassified ENV/JM/MONO(2016)29/ANN1 ENV/JM/MONO(2016)29/ANN1 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 27-Oct-2016

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/94528/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ANNEX TO GUIDELINE

More information

S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers

S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers Current version dated 8 June 2016 International Council for Harmonisation of

More information

Strategies for grouping chemicals to fill data gaps to assess genetic toxicity and genotoxic carcinogenicity

Strategies for grouping chemicals to fill data gaps to assess genetic toxicity and genotoxic carcinogenicity User manual Strategies for grouping chemicals to fill data Part N - The sub-title For the latest news and the most up-todate information, please consult the ECHA website. genotoxic carcinogenicity Document

More information

Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products

Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products Table of contents 1.Introduction...2 2.Scope...3 3.Discussion...4 3.1. Chemistry, manufacturing, and controls...4

More information

参考資料. Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products. Draft

参考資料. Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products. Draft 参考資料 1 2 3 4 5 Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products Draft 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Table of contents 1.

More information

QSAR APPLICATION TOOLBOX, v 4.1 BASIC PRACTICAL TRAINING WORKSHOP. BARCELONA, SPAIN November, 2017 AGENDA

QSAR APPLICATION TOOLBOX, v 4.1 BASIC PRACTICAL TRAINING WORKSHOP. BARCELONA, SPAIN November, 2017 AGENDA QSAR APPLICATION TOOLBOX, v 4.1 BASIC PRACTICAL TRAINING WORKSHOP BARCELONA, SPAIN 20-21 November, 2017 AGENDA Monday, 20 November 2017 (09:00 17:00) 09:00-09:30 Registration and Toolbox loading onto computers.

More information

Toxicological Assessment of (silver) Nanomaterials: Challenges and Pitfalls

Toxicological Assessment of (silver) Nanomaterials: Challenges and Pitfalls Dr Helinor Johnston, Nano Safety Research Group Toxicological Assessment of (silver) Nanomaterials: Challenges and Pitfalls BfR Conference: Nanosilver Feb 2012 h.johnston@hw.ac.uk Nanotoxicology Nanotechnology

More information

COMMUNICATION FROM THE COMMISSION. on the European Citizens' Initiative "Stop Vivisection"

COMMUNICATION FROM THE COMMISSION. on the European Citizens' Initiative Stop Vivisection EUROPEAN COMMISSION Brussels, 3.6.2015 C(2015) 3773 final COMMUNICATION FROM THE COMMISSION on the European Citizens' Initiative "Stop Vivisection" EN EN 1. INTRODUCTION "Stop Vivisection" is the third

More information

Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products

Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products 1 2 3 17 January 2013 EMA/CHMP/13099/2013 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Joint MHLW/EMA reflection paper on the development of block copolymer micelle Agreed by Nanomedicines

More information

Strategies for Assessment of Immunotoxicology in Preclinical Drug Development

Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Rebecca Brunette, PhD Scientist, Analytical Biology SNBL USA Preclinical Immunotoxicology The study of evaluating adverse effects

More information

COMMISSION STAFF WORKING DOCUMENT IMPACT ASSESSMENT

COMMISSION STAFF WORKING DOCUMENT IMPACT ASSESSMENT EUROPEAN COMMISSION Brussels, 15.6.2016 SWD(2016) 211 final PART 4/16 COMMISSION STAFF WORKING DOCUMENT IMPACT ASSESSMENT Defining criteria for identifying endocrine disruptors in the context of the implementation

More information

Evaluation of Alternative Methods for Assessing Acute Toxicity of Mixtures. Raja S. Settivari, BVSc&AH, PhD, DABT Dow Chemical Company

Evaluation of Alternative Methods for Assessing Acute Toxicity of Mixtures. Raja S. Settivari, BVSc&AH, PhD, DABT Dow Chemical Company Evaluation of Alternative Methods for Assessing Acute Toxicity of Mixtures Raja S. Settivari, BVSc&AH, PhD, DABT Dow Chemical Company 1 Purpose Evaluation of alternative methods for: Testing formulations/mixtures

More information

OECD QSAR Toolbox Version 3.1

OECD QSAR Toolbox Version 3.1 OECD QSAR Toolbox Version 3.1 Strategies for grouping chemicals to fill data gaps to assess genetic toxicity and genotoxic carcinogenicity (where covalent DNA binding is the molecular initiating event)

More information

ACVM - REGISTRATION STANDARD FOR TOXICOLOGY AND ENVIRONMENTAL TOXICOLOGY

ACVM - REGISTRATION STANDARD FOR TOXICOLOGY AND ENVIRONMENTAL TOXICOLOGY ACVMS 9.1 Ministry of Agriculture and Forestry Post Office Box 2526 WELLINGTON, NEW ZEALAND ACVM - REGISTRATION STANDARD FOR TOXICOLOGY AND ENVIRONMENTAL TOXICOLOGY This document may be altered at any

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR

More information

What are ATMP s: Why do they Require Special Scientific and Regulatory Attention? Christopher A Bravery.

What are ATMP s: Why do they Require Special Scientific and Regulatory Attention? Christopher A Bravery. What are ATMP s: Why do they Require Special Scientific and Regulatory Attention? Christopher A Bravery cbravery@advbiols.com CONTENTS What are ATMP s Definitions What makes ATMP s different? Starting

More information

OECD GUIDELINE FOR THE TESTING OF CHEMICALS

OECD GUIDELINE FOR THE TESTING OF CHEMICALS OECD GUIDELINE FOR THE TESTING OF CHEMICALS DRAFT PROPOSAL FOR A NEW TEST GUIDELINE In Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method INTRODUCTION 1. A skin sensitizer refers to a substance

More information

THE FUTURE OF IN VITRO SCREENING IN THE DEVELOPMENT OF NEW DRUGS. Hajime Kojima, JaCVAM, NIHS, Japan

THE FUTURE OF IN VITRO SCREENING IN THE DEVELOPMENT OF NEW DRUGS. Hajime Kojima, JaCVAM, NIHS, Japan THE FUTURE OF IN VITRO SCREENING IN THE DEVELOPMENT OF NEW DRUGS Hajime Kojima, JaCVAM, NIHS, Japan 1 3Rs of animal use (Russel and Burch 1959) Reduction (of animal use) Refinement (to lessen pain or distress

More information

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited. Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics

More information

ISO INTERNATIONAL STANDARD. Biological evaluation of medical devices Part 1: Evaluation and testing within a risk management process

ISO INTERNATIONAL STANDARD. Biological evaluation of medical devices Part 1: Evaluation and testing within a risk management process INTERNATIONAL STANDARD ISO 10993-1 Fourth edition 2009-10-15 Biological evaluation of medical devices Part 1: Evaluation and testing within a risk management process Évaluation biologique des dispositifs

More information

Guidance for Industry

Guidance for Industry Reprinted from FDA s website by Guidance for Industry Scientific Considerations in Demonstrating Biosimilarity to a Reference Product DRAFT GUIDANCE This guidance document is being distributed for comment

More information

EURL ECVAM Test Submission Template (TST)

EURL ECVAM Test Submission Template (TST) EURL ECVAM Test Submission Template (TST) U-SENS Test Submission Template Page 1 of 56 TABLE OF CONTENTS SUBMISSION OF CONFIDENTIAL INFORMATION... 4 LIST OF ABBREVIATIONS... 4 SUBMITTER S REQUEST TO ECVAM...

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES NON-AMPLIFIABLE IN EUKARYOTIC CELLS FOR VETERINARY USE

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES NON-AMPLIFIABLE IN EUKARYOTIC CELLS FOR VETERINARY USE The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Veterinary Use CVMP/IWP/07/98-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES

More information

Track III: International Clinical Trials: Global Compliance Norms and EU Focus

Track III: International Clinical Trials: Global Compliance Norms and EU Focus Track III: International Clinical Trials: Global Compliance Norms and EU Focus EU Focus Emmanuelle Voisin, PhD Principal, Voisin Consulting May 2008 Rationale Clinical trials in EU important part of health

More information

Guideline for the Quality, Safety, and Efficacy Assurance of Follow-on Biologics

Guideline for the Quality, Safety, and Efficacy Assurance of Follow-on Biologics Provisional Translation (as of April 19, 2013) PFSB/ELD Notification No. 0304007 March 4, 2009 To: Prefectural Health Department (Bureau) From: Evaluation and Licensing Division, Pharmaceutical and Food

More information

The challenges of potency assay development for cell-based medicinal products in Europe

The challenges of potency assay development for cell-based medicinal products in Europe Focus Advanced therapies 5 The challenges of potency assay development for cell-based medicinal products in Europe Authors Valerie Pimpaneau, Senior Director, Voisin Consulting Life Sciences; François

More information

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP)

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) European Medicines Agency Evaluation of Medicines for Human Use London, 16 June 2005 EMEA/CHMP/94526/2005 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) ANNEX GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS

More information

The European partnership for alternative approaches to animal testing

The European partnership for alternative approaches to animal testing AATEX 14, Special Issue, 769-773 Proc. 6th World Congress on Alternatives & Animal Use in the Life Sciences August 21-25, 2007, Tokyo, Japan The European partnership for alternative approaches to animal

More information

Non-clinical Assessment Requirements

Non-clinical Assessment Requirements Non-clinical Assessment Requirements Presented by: Maria Nieto-Gutierrez Safety and Efficacy of Medicines/Human Medicines Development and Evaluation An agency of the European Union Contents: Relevance

More information

Cytomics in Action: Cytokine Network Cytometry

Cytomics in Action: Cytokine Network Cytometry Cytomics in Action: Cytokine Network Cytometry Jonni S. Moore, Ph.D. Director, Clinical and Research Flow Cytometry and PathBioResource Associate Professor of Pathology & Laboratory Medicine University

More information

DRAFT GUIDANCE DOCUMENT ON AN INTEGRATED APPROACH ON TESTING AND ASSESSMENT (IATA) FOR SERIOUS EYE DAMAGE AND EYE IRRITATION DRAFT VERSION 1 SUMMARY:

DRAFT GUIDANCE DOCUMENT ON AN INTEGRATED APPROACH ON TESTING AND ASSESSMENT (IATA) FOR SERIOUS EYE DAMAGE AND EYE IRRITATION DRAFT VERSION 1 SUMMARY: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 DRAFT GUIDANCE DOCUMENT ON AN INTEGRATED APPROACH ON TESTING AND ASSESSMENT (IATA) FOR SERIOUS EYE DAMAGE AND

More information

Testing of chemicals for classification according to REACH and GHS

Testing of chemicals for classification according to REACH and GHS Testing of chemicals for classification according to REACH and GHS Norbert Bornatowicz, Head Toxicology Seibersdorf Labor GmbH 2444 Seibersdorf, AUSTRIA Overview on the presentation Classification: IUCLID

More information

Testing of chemicals for classification according to REACH and GHS

Testing of chemicals for classification according to REACH and GHS Testing of chemicals for classification according to REACH and GHS Norbert Bornatowicz, Head Toxicology Seibersdorf Labor GmbH 2444 Seibersdorf, AUSTRIA Overview on the presentation Classification: IUCLID

More information

Safety data sheet according to 1907/2006/EC, Article 31

Safety data sheet according to 1907/2006/EC, Article 31 Page 1/6 * SECTION 1: Identification of the substance/mixture and of the company/ undertaking 1.1 Product identifier 1.2 Relevant identified uses of the substance or mixture and uses advised against No

More information

Justification of Specifications (JOS): What Product and Process Development was all About. Christopher A Bravery

Justification of Specifications (JOS): What Product and Process Development was all About. Christopher A Bravery Justification of Specifications (JOS): What Product and Process Development was all About Christopher A Bravery cbravery@advbiols.com 1 The Importance of Characterisation 2 http://www.advbiols.com/documents/importance

More information

Printed paper and board: Priority setting strategy for toxicological assessment

Printed paper and board: Priority setting strategy for toxicological assessment Printed paper and board: Priority setting strategy for toxicological assessment M. Van Bossuyt 1,2, E. Van Hoeck 1, T. Vanhaecke 2, V. Rogiers 2* and B. Mertens 1* 1 Food, Medicines and Consumer Safety,

More information

G R O U P E M E N T D I N T E R E T S C I E N T I F I Q U E

G R O U P E M E N T D I N T E R E T S C I E N T I F I Q U E G R O U P E M E N T D I N T E R E T S C I E N T I F I Q U E Plateforme française pour le développement des méthodes alternatives en expérimentation animale RAPPORT A MADAME LA MINISTRE DE L ENSEIGNEMENT

More information

Epigenetics, Environment and Human Health

Epigenetics, Environment and Human Health Epigenetics, Environment and Human Health A. Karim Ahmed National Council for Science and the Environment Washington, DC May, 2015 Epigenetics A New Biological Paradigm A Question about Cells: All cells

More information

Identification and Characterization of Adverse Effects in 21 st Century Toxicology and Risk Assessment

Identification and Characterization of Adverse Effects in 21 st Century Toxicology and Risk Assessment Identification and Characterization of Adverse Effects in 21 st Century Toxicology and Risk Assessment Daland R. Juberg, PhD Dow AgroSciences Douglas A. Keller, PhD Sanofi US 13 June 2012 SOT Risk Assessment

More information

Skin Sensitisation and Epidermal Disposition: The Relevance of Epidermal Disposition for Sensitisation Hazard Identification and Risk Assessment

Skin Sensitisation and Epidermal Disposition: The Relevance of Epidermal Disposition for Sensitisation Hazard Identification and Risk Assessment ATLA 35, 137 154, 2007 137 Skin Sensitisation and Epidermal Disposition: The Relevance of Epidermal Disposition for Sensitisation Hazard Identification and Risk Assessment The Report and Recommendations

More information

SUBMISSION OF COMMENTS ON The Requirements for First-in-Human Clinical Trials for Potential High Risk Medicinal Products EMEA/CHMP/SWP/28367/2007

SUBMISSION OF COMMENTS ON The Requirements for First-in-Human Clinical Trials for Potential High Risk Medicinal Products EMEA/CHMP/SWP/28367/2007 European Medicines Agency SUBMISSION OF COMMENTS ON The Requirements for First-in-Human Clinical Trials for Potential High Risk Medicinal Products EMEA/CHMP/SWP/28367/2007 COMMENTS FROM The Biotechnology

More information

Non-clinical documentation Overview of Requirements

Non-clinical documentation Overview of Requirements 3 rd EMEA-. Non-clinical Aspects Non-clinical documentation Overview of Requirements EMEA Pre-Authorisation Human Unit 3 rd EMEA-. Non-clinical Aspects Outline Overview of Legal and Regulatory requirements

More information

Testing Methods and Directives

Testing Methods and Directives EUROPEAN COMMISSION DIRECTORATE GENERAL - JRC JOINT RESEARCH CENTRE Institute for Health and Consumer Protection Unit: Toxicology and Chemical Substances European Chemicals Bureau D:\My Documents\JR\Tables\OFFJOUR\Listofoj.doc

More information

PHYSIOLOGICALLY-BASED KINETIC MODELLING IN RISK ASSESSMENT REACHING A WHOLE NEW LEVEL IN REGULATORY DECISION-MAKING At a glance*

PHYSIOLOGICALLY-BASED KINETIC MODELLING IN RISK ASSESSMENT REACHING A WHOLE NEW LEVEL IN REGULATORY DECISION-MAKING At a glance* The European Commission s science and knowledge service Joint Research Centre PHYSIOLOGICALLY-BASED KINETIC MODELLING IN RISK ASSESSMENT REACHING A WHOLE NEW LEVEL IN REGULATORY DECISION-MAKING At a glance*

More information

Biological evaluation of medical devices --

Biological evaluation of medical devices -- Translated English of Chinese Standard: GB/T16886.1-2011 Translated by: www.chinesestandard.net Wayne Zheng et al. Email: Sales@ChineseStandard.net ICS 11.040.01 C 30 NATIONAL STANDARD OF THE PEOPLE S

More information

Current challenges from Evaluation point of view - Introduction case studies

Current challenges from Evaluation point of view - Introduction case studies Current challenges from Evaluation point of view - Introduction case studies Expert Workshop Dealing with Uncertainty of Non-Test Methods under REACH 23-24 September 2010 Wim De Coen ECHA Evaluation I

More information

Cost Reduction in REACH Alternatives to Testing ChemicalWatch EXPO Berlin, April 2017 Peter Jenkinson CEHTRA

Cost Reduction in REACH Alternatives to Testing ChemicalWatch EXPO Berlin, April 2017 Peter Jenkinson CEHTRA Consultancy for Environmental and Human Toxicology and Risk Assessment Science Beyond Regulatory Compliance Cost Reduction in REACH Alternatives to Testing ChemicalWatch EXPO Berlin, April 2017 Peter Jenkinson

More information

Possibilities for a New Approach to Chemicals Risk Assessment The Report of a FRAME Workshop a

Possibilities for a New Approach to Chemicals Risk Assessment The Report of a FRAME Workshop a ATLA 34, 621 649, 2006 621 Possibilities for a New Approach to Chemicals Risk Assessment The Report of a FRAME Workshop a Robert Combes, 1 Michael Balls, 1 Paul Illing, 2 Nirmala Bhogal, 1 Jonathan Dale,

More information

Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug development

Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug development 1 2 3 24 June 2010 EMA/CHMP/641298/2008 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug

More information

The Road to Functional Bioanalysis: Development and Validation of a Cell-Based Assay for Neutralizing Anti-Drug Antibody Analysis

The Road to Functional Bioanalysis: Development and Validation of a Cell-Based Assay for Neutralizing Anti-Drug Antibody Analysis The Road to Functional Bioanalysis: Development and Validation of a Cell-Based Assay for Neutralizing Anti-Drug Antibody Analysis Christelle Pythoud, PhD 2 nd EBF YSS, Barcelona Spain Celerion Switzerland

More information

ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions. Step 3

ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions. Step 3 European Medicines Agency June 2009 EMEA/CHMP/ICH/380636/2009 ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions Step 3 NOTE FOR GUIDANCE

More information

Stem Cell Services. Driving Innovation for Stem Cell Researchers

Stem Cell Services. Driving Innovation for Stem Cell Researchers Driving Innovation for Stem Cell Researchers Stem Cell Services Partner with us and have access to the most advanced and comprehensive stem cell services available today. 675 W. Kendall St. Cambridge,

More information

Safety data sheet according to 1907/2006/EC, Article 31

Safety data sheet according to 1907/2006/EC, Article 31 Page 1/6 * SECTION 1: Identification of the substance/mixture and of the company/ undertaking 1.1 Product identifier - Investment BS Liquid 1, Investment BS Liquid 2,Investment Special BS Liquid 3 for

More information

DRAFT KEY EVENT BASED TEST GUIDELINES 442D. In Vitro Skin Sensitisation assays addressing the AOP Key Event on: Keratinocyte activation

DRAFT KEY EVENT BASED TEST GUIDELINES 442D. In Vitro Skin Sensitisation assays addressing the AOP Key Event on: Keratinocyte activation DRAFT KEY EVENT BASED TEST GUIDELINES 442D In Vitro Skin Sensitisation assays addressing the AOP Key Event on: Keratinocyte activation GENERAL INTRODUCTION Keratinocyte activation Key Event based Test

More information

CQAs for C&GT Products to Enable Comparability Assessment. Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline

CQAs for C&GT Products to Enable Comparability Assessment. Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline CQAs for C&GT Products to Enable Comparability Assessment Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline Overview Demonstrate the value of defining CQAs early in product development

More information

Endocrine discuptors under REACH

Endocrine discuptors under REACH Endocrine discuptors under REACH 8. BfR Forum Verbraucherschutz "When substances affect the endocrine system Possible health risks of endocrine disruptors" 20-21 April 2010 Dr. Gabriele Schö Schöning ECHA

More information

US EPA Perspectives on GHS SCHC Fall Meeting. Kaitlin Keller, Pesticide Re-evaluation Division Office of Pesticide Programs, USEPA September 27, 2017

US EPA Perspectives on GHS SCHC Fall Meeting. Kaitlin Keller, Pesticide Re-evaluation Division Office of Pesticide Programs, USEPA September 27, 2017 1 US EPA Perspectives on GHS SCHC Fall Meeting Kaitlin Keller, Pesticide Re-evaluation Division Office of Pesticide Programs, USEPA September 27, 2017 2 Background: GHS GHS was adopted by the UN in 2003;

More information

Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development

Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development Unclassified ENV/JM/MONO(2016)58 ENV/JM/MONO(2016)58 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 04-Nov-2016 English

More information

Evaluation of (Q)SAR models for the prediction of mutagenicity potential

Evaluation of (Q)SAR models for the prediction of mutagenicity potential AATEX 14, Special Issue, 469-473 Proc. 6th World Congress on Alternatives & Animal Use in the Life Sciences August 21-25, 2007, Tokyo, Japan Evaluation of (Q)SAR models for the prediction of mutagenicity

More information

Outcomes in Mesenchymal Stem Cell Manufacturing. Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL

Outcomes in Mesenchymal Stem Cell Manufacturing. Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL Outcomes in Mesenchymal Stem Cell Manufacturing Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL Background HCTL established in 1992 to support BMT programs of Mayo

More information

Development of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the application of the risk-based approach

Development of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the application of the risk-based approach 3 July 2017 EMA/CAT/216556/2017 Inspections, Human Medicines, Pharmacovigilance and Committees Division Development of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the

More information

Guidance for Establishing Safety in First-in-Human Studies during Drug Development CONTENTS SUMMARY INTRODUCTION SCOPE

Guidance for Establishing Safety in First-in-Human Studies during Drug Development CONTENTS SUMMARY INTRODUCTION SCOPE Guidance for Establishing Safety in First-in-Human Studies during Drug Development CONTENTS SUMMARY...1 1. INTRODUCTION...1 2. SCOPE...2 3. MAIN GUIDANCE TEXT...2 3.1 Risk Factors...2 3.1.1 Mechanism of

More information

GMO RISK ANALYSIS. Hennie Groenewald, Jhill Johns & James Rhodes. GMASSURE Capacity Building, Windhoek, Nov 2014

GMO RISK ANALYSIS. Hennie Groenewald, Jhill Johns & James Rhodes. GMASSURE Capacity Building, Windhoek, Nov 2014 GMO RISK ANALYSIS Hennie Groenewald, Jhill Johns & James Rhodes GMASSURE Capacity Building, Windhoek, 17-21 Nov 2014 Department: Science and Technology REPUBLIC OF SOUTH AFRICA concepts IMPORTANT BACKGROUND

More information

Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines

Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines Annex 2 Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines Introduction 61 Background 62 Scope 62 General considerations 63 Terminology 65 Part A. Manufacturing and quality

More information

Preclinical Drug Development

Preclinical Drug Development Preclinical Drug Development A guidance prepared by From a 2004 NIH Summit Workshop: A major reason for the tremendous cost of drug development is the high rate of drug candidate failure during clinical

More information

FDA Public Hearing: Approval Pathway for Biosimilar. Products. November 2-3, 2010

FDA Public Hearing: Approval Pathway for Biosimilar. Products. November 2-3, 2010 FDA Public Hearing: Approval Pathway for Biosimilar and Interchangeable Biological Products November 2-3, 2010 1 The Biotechnology Industry Organization Over 1,100 members, including biotechnology companies,

More information

OECD RECOMMENDATION ON THE SAFETY OF NANOMATERIALS

OECD RECOMMENDATION ON THE SAFETY OF NANOMATERIALS OECD RECOMMENDATION ON THE SAFETY OF NANOMATERIALS Workshop for the Asia-Pacific Region on Nanotechnology and Manufactured Nanomaterials: Safety Issues 10-11 September 2015, Bangkok, Thailand OECD Australia

More information

Beth Hutchins, PhD PhRMA ICH Gene Therapy Discussion Group

Beth Hutchins, PhD PhRMA ICH Gene Therapy Discussion Group ICH Considerations on General Principles to Address the Risk of Inadvertent Germline Integration of Gene Therapy Vectors and Current Topics on Gene Therapy in USA Beth Hutchins, PhD PhRMA ICH Gene Therapy

More information

Biosimilar regulation in Republic of Korea and Asia-Pacific Economic Cooperation (APEC) developments

Biosimilar regulation in Republic of Korea and Asia-Pacific Economic Cooperation (APEC) developments Biosimilar regulation in Republic of Korea and Asia-Pacific Economic Cooperation (APEC) developments Ministry of Food and Drug Safety Jeewon Joung Outline I. Korean Regulatory Framework for Biosimilar

More information

Current State of the Science in Chemical Risk Assessment

Current State of the Science in Chemical Risk Assessment Current State of the Science in Chemical Risk Assessment M.E. (Bette) Meek McLaughlin Centre University of Ottawa, Ottawa, Canada Email:bmeek@uottawa.ca Outline The Evolution of Regulatory Mandates & Implications

More information

GP 4 G SP biofunctional Helps energize and protect skin from environmental stresses, to enhance maintenance and repair. Ashland Specialty Ingredients

GP 4 G SP biofunctional Helps energize and protect skin from environmental stresses, to enhance maintenance and repair. Ashland Specialty Ingredients Helps energize and protect skin from environmental stresses, to enhance maintenance and repair 1 1 Helps energize and protect skin from environmental stresses, to enhance maintenance and repair. A Description

More information

The Integrated Biomedical Sciences Graduate Program

The Integrated Biomedical Sciences Graduate Program The Integrated Biomedical Sciences Graduate Program at the university of notre dame Cutting-edge biomedical research and training that transcends traditional departmental and disciplinary boundaries to

More information

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report

More information

Biosimilar Monoclonal Antibodies: Registration Requirements. Henry M. J. Leng

Biosimilar Monoclonal Antibodies: Registration Requirements. Henry M. J. Leng Biosimilar Monoclonal Antibodies: Registration Requirements Henry M. J. Leng Disclaimer This presentation is given in my personal capacity and represents only the author s personal views and does not represent

More information

Safety data sheet according to 1907/2006/EC, Article 31

Safety data sheet according to 1907/2006/EC, Article 31 Page 1/7 * SECTION 1: Identification of the substance/mixture and of the company/ undertaking 1.1 Product identifier Trade name Emcoril B VM 1.2 Relevant identified uses of the substance or mixture and

More information

Current situation on nonclinical safety evaluation of regenerative medical products in Japan

Current situation on nonclinical safety evaluation of regenerative medical products in Japan Current situation on nonclinical safety evaluation of regenerative medical products in Japan Takuya Nishimura Office of Cellular and Tissue based Products PMDA Disclaimers The views expressed in this presentation

More information

PROPOSAL THE SCIENTIFIC COMMITTEE ON COSMETIC PRODUCTS AND NON-FOOD PRODUCTS

PROPOSAL THE SCIENTIFIC COMMITTEE ON COSMETIC PRODUCTS AND NON-FOOD PRODUCTS THE SCIENTIFIC COMMITTEE ON COSMETIC PRODUCTS AND NON-FOOD PRODUCTS INTENDED FOR CONSUMERS PROPOSAL FOR A STRATEGY FOR TESTING HAIR DYE COSMETIC INGREDIENTS FOR THEIR POTENTIAL GENOTOXICITY/MUTAGENICITY

More information

INTRODUCTION TO PHARMACOLOGY

INTRODUCTION TO PHARMACOLOGY INTRODUCTION TO PHARMACOLOGY Pharmacology is the study of how chemicals interact with the body Endogenous hormones, growth factors, etc Exogenous drugs Two areas of study Pharmacodynamics Interaction of

More information

ICH Considerations on Viral/Vector Shedding; and Overview of Gene Therapy Activity in Canada

ICH Considerations on Viral/Vector Shedding; and Overview of Gene Therapy Activity in Canada ICH Considerations on Viral/Vector Shedding; and Overview of Gene Therapy Activity in Canada Anthony Ridgway, Ph.D. Senior Regulatory Scientist Biologics & Genetic Therapies Directorate Health Canada Open

More information